Skip to main content
. 2016 May 24;2:97–105. doi: 10.1016/j.pvr.2016.05.003

Table 2.

Univariate analysis of risk factors for prevalent composite-HSIL in the Study of the Prevention of Anal Cancer, overall and stratified by composite-AIN2 and composite-AIN3 diagnoses.

Composite-HSIL versus composite-negativea(n=415)
Composite-AIN2 versus composite-negativeb(n=234)
Composite-AIN3 versus Composite-negativec(n=364)
Variable n (%) OR (95% CI) p-Value n (%) OR (95% CI) p-Value n (%) OR (95% CI) p-Value
Age 35–44 years 74/131 (56.5) 1.00 0.577 21/78 (26.9) 1.00 0.113 53/110 (48.2) 1.00 0.991
45–54 years 89/161 (55.3) 0.95 (0.60–1.52) 18/90 (20.0) 0.68 (0.33–1.40) 71/143 (49.7) 1.06 (0.64–1.75)
55–64 years 52/84 (61.6) 1.25 (0.71–2.20) 10/42 (23.8) 0.85 (0.35–2.03) 42/74 (56.8) 1.41 (0.78–2.56)
65+ years 17/39 (43.6) 0.60 (0.29–1.23) 2/24 (8.3) 0.25 (0.05–1.18) 15/37 (40.5) 0.73 (0.34–1.57)
HIV status HIV-negative 128/263 (48.7) 1.00 <0.0011 30/165 (18.2) 1.00 0.0401 98/233 (42.1) 1.00 <0.0011
HIV-positive 104/152 (68.4) 2.29 (1.50–3.47) 21/69 (30.4) 1.97 (1.03–3.76) 83/131 (63.4) 2.38 (1.53–3.70)


 

 

 

 

 

 

 

 

 

 


Smoking status Never 120/223 (53.8) 1.00 0.104 26/129 (20.2) 1.00 0.586 94/197 (47.7) 1.00 0.084
Past 76/138 (55.1) 1.05 (0.69–1.61) 18/80 (22.5) 1.15 (0.58–2.25) 58/120 (48.3) 1.03 (0.65–1.61)
Current ≤10PY 12/19 (63.2) 1.47 (0.56–3.88) 5/12 (41.7) 2.83 (0.83–9.64) 7/14 (50.0) 1.10 (0.37–3.24)
Current >10PY 24/35 (68.6) 1.87 (0.88–4.01) 2/13 (15.4) 0.72 (0.15–3.45) 22/33 (66.7) 2.19 (1.01–4.76)
HPV16 status Negative 114/273 (41.8) 1.00 <0.0011 40/199 (20.1) 1.00 0.0931 74/233 (31.8) 1.00 <0.0011
Positive 114/136 (83.8) 7.23 (4.31–12.11) 11/33 (33.3) 1.99 (0.89–4.43) 103/125 (82.4) 10.06 (5.88–17.20)


 

 

 

 

 

 

 

 

 

 


Number of HR-HPV types 0 25/134 (18.7) 1.00 <0.001 9/118 (7.6) 1.00 <0.001 16/125 (12.8) 1.00 <0.001
1 55/98 (56.1) 5.58 (3.09–10.06) 10/53 (18.9) 2.82 (1.07–7.41) 45/88 (51.1) 7.13 (3.65–13.94)
2 66/84 (78.6) 16.00 (8.11–31.51) 17/35 (48.6) 11.44 (4.43–29.56) 49/67 (73.1) 18.55 (8.73–39.38)
3+ 82/93 (88.2) 32.50 (15.16–69.83) 15/26 (57.7) 16.52 (5.88–46.41) 67/78 (85.9) 41.49 (18.17–94.76)


 

 

 

 

 

 

 

 

 

 


Lifetime receptive partners with a condom 0–1 5/24 (20.8) 1.00 <0.001 0/19 <0.001 5/24 (20.8) 1.00 <0.001
2–5 19/52 (36.5) 2.19 (0.69–6.96) 2/35 (5.7) N/A 17/50 (34.0) 1.96 (0.61–6.27)
6–10 25/42 (59.5) 5.59 (1.58–19.75) 4/21 (19.1) N/A 21/38 (55.3) 4.69 (1.33–16.53)
>10 176/286 (61.5) 6.08 (2.15–17.22) 45/155 (29.0) N/A 131/241 (54.4) 4.53 (1.60–12.79)


 

 

 

 

 

 

 

 

 

 


Lifetime receptive partners without a condom 0–1 18/63 (28.6) 1.00 <0.001 4/49 (8.2) 1.00 0.018 14/59 (23.7) 1.00 <0.001
2–5 52/105 (49.5) 2.45 (1.24–4.86) 18/71 (25.4) 3.82 (1.17–12.53) 34/87 (39.1) 2.06 (0.97–4.37
6–10 56/85 (65.9) 4.83 (2.25–10.36) 5/34 (14.7) 1.94 (0.47–7.95) 51/80 (63.8) 5.65 (2.48–12.88)
>10 106/162 (65.4) 4.73 (2.41–9.30) 24/80 (30.0) 4.82 (1.49–15.57) 82/138 (59.4) 4.71 (2.27–9.78)


 

 

 

 

 

 

 

 

 

 


Previous six months, receptive partners with a condom None 91/180 (50.6) 1.00 0.022 13/102 (12.8) 1.00 <0.001 78/167 (46.7) 1.00 0.194
One 40/70 (57.1) 1.30 (0.75–2.28) 8/38 (21.1) 1.83 (0.68–4.87) 32/62 (51.6) 1.22 (0.68–2.19)
2–5 53/94 (56.4) 1.26 (0.76–2.09) 15/56 (26.8) 2.50 (1.08–5.83) 38/79 (48.1) 1.06 (0.62–1.81)
>5 48/71 (67.6) 2.04 (1.14–3.66) 15/38 (39.5) 4.46 (1.78–11.17) 33/56 (58.9) 1.64 (0.88–3.04)


 

 

 

 

 

 

 

 

 

 


Previous six months, receptive partners without a condom None 103/197 (52.3) 1.00 0.004 16/110 (14.6) 1.00 <0.001 87/181 (48.1) 1.00 0.054
One 62/121 (51.2) 0.96 (0.61–1.51) 14/73 (19.2) 1.39 (0.63–3.08) 48/107 (44.9) 0.88 (0.54–1.42)
2–5 39/62 (62.9) 1.55 (0.86–2.79) 12/35 (34.3) 3.07 (1.25–7.54) 27/50 (54.0) 1.27 (0.68–2.38)
>5 28/35 (80.0) 3.65 (1.49–8.93) 9/16 (56.3) 7.55 (2.27–25.09) 19/26 (73.1) 2.93 (1.16–7.42)

Numbers do not always add up to column totals because of small amounts of missing data.

PY: Pack Years.

1 Score test of homogeneity, else the p-values presented are score test for trend of odds.

a Comparing men with composite negative result (n=183) to men with HSIL detected on by either cytology or histology (n=232).

b Comparing men with composite negative result (n=183) to men with HSIL-AIN2 on cytology and/or AIN2 on histology without a diagnosis of AIN3 on either (n=51).

c Comparing men with composite negative result (n=183) to men with HSIL-AIN3 on cytology or histology (n=181).

Men in the composite-LSIL (n=155) and composite-ASC-H (n=55) were excluded from analyses of risk factors.

Row percentages presented.